Lakewood — Amedex wins IRB approval for Phase 2a Nu — 3 diabetic foot ulcer trial

Lakewood-Amedex won central IRB clearance for its Phase 2a Nu-3 trial in mildly infected diabetic foot ulcers. All participating sites also secured IRB sign-off, clearing the way to start patient enrollment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via (Ref. ID: NY51161) on September 18, 2026, and is solely responsible for the information contained therein. (C)